Epstein-Barr virus-associated lymphoproliferative disorders have been frequently reported as a complication of solid organ and allogeneic bone marrow transplantation. Their occurrence is rare after autologous bone marrow transplantation (BMT) with only five published reports in the literature. We report two cases of posttransplant lymphoproliferative disorder occurring after autologous BMT for Hodgkin's disease and non-Hodgkin's lymphoma. Post-transplant lymphoproliferative disorders can occur after autologous BMT and should be included in the differential diagnosis of patients with persistent fever, adenopathy or pulmonary infiltrates. Keywords: PTLD; EBV; BMT; lymphoproliferation Post-transplant lymphoproliferative disorders (PTLD) are a well recognized complication of solid organ transplantation and are due to an unrestricted proliferation of Epstein-Barr virus (EBV)-infected lymphocytes occurring with immunosuppression.
Post-transplant lymphoproliferative disorders (PTLD) are a well recognized complication of solid organ transplantation and are due to an unrestricted proliferation of Epstein-Barr virus (EBV)-infected lymphocytes occurring with immunosuppression. 1, 2 The majority of PTLD are of B cell origin; however, cases of T cell PTLD and Hodgkin's disease have been reported. [2] [3] [4] Pathologically, the lymphoproliferation encompasses a spectrum ranging from plasma cell hyperplasia and polymorphic B cell hyperplasia (similar to infectious mononucleosis), to monomorphic infiltrates indistinguishable from malignant lymphoma. 2, 5, 6 The risk for developing PTLD after solid organ transplantation is increased 20-to 150-fold compared to the incidence of lymphoma in the general population. The risk is greatest within the first year after transplant. [7] [8] [9] PTLD have been reported after allogeneic bone marrow transplantation (BMT) with an increased incidence after T cell depletion. 10, 11 In contrast to the experience with PTLD after allogeneic BMT, PTLD after autologous BMT is infrequent. [12] [13] [14] [15] We present two patients who developed PTLD after autologous BMT.
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Case reports

Patient 1
A 27-year-old male with stage IIA nodular sclerosing Hodgkin's disease relapsed after treatment with doxorubicin, bleomycin, vincristine and dacarbazine. He received two cycles of mechlorethamine, vincristine, procarbazine and prednisone (MOPP) and then received high-dose cyclophosphamide, carmustine and etoposide followed by autologous BMT. Following transplant, 4500 cGy consolidation radiation therapy was given to the mediastinum.
On day +87, he developed dyspnea and bilateral pulmonary infiltrates. Bronchoalveolar lavage was nondiagnostic. Low grade fevers and dyspnea persisted after empiric antibiotic therapy.
After referral to our institution, a video-assisted thoracoscopy was performed. Pneumocystis carinii pneumonia (PCP) and cytomegalovirus (CMV) pneumonitis were diagnosed.
Sulfamethoxazole/trimethroprim, ganciclovir (2.5 mg/kg every 8 h i.v.), immune globulin and prednisone were administered with prompt clinical improvement. Recurrent pneumothoraces required pleural stripping. A mediastinal lymph node biopsy showed plasmacytic hyperplasia and stained positive for EBV latent membrane protein (LMP) (Figure 1 ). Immunohistochemical staining for kappa and lambda chains demonstrated a polyclonal plasma cell population. He expired on day +159.
At autopsy, he was found to have disseminated polymorphous B cell PTLD involving the mediastinal, perigastric and peripancreatic lymph nodes as well as the pulmonary parenchyma.
Patient 2
A 67-year-old female with stage II follicular large cell non-Hodgkin's lymphoma (NHL) relapsed after treatment with cyclophosphamide, mitoxantrone, vincristine and prednisone.
She received high-dose carmustine, etoposide, cytarabine and cyclophosphamide followed by autologous BMT. Acyclovir (800 mg orally twice a day) was initiated due to positive herpes simplex serology.
On day +38, she developed low-grade fever. Immunoblasts with atypical lymphocytes were detected on peripheral blood smear. A clonal B lymphocyte population was identified by Southern analysis with JH DNA probe in the peripheral blood and bone marrow.
One week later, she had seizures followed by respiratory failure. Flow cytometry of the peripheral blood, bone marrow and spinal fluid demonstrated a population of CD45, CD19, CD20, HLA-DR, variable CD24-positive B cells. Southern analysis confirmed the presence of EBV genome. On day +48, she expired.
Post mortem study showed extensive infiltration of the lungs, heart, spleen, kidneys, adrenal glands, pituitary gland and central nervous system (cortex, meninges and spinal cord) by a polymorphic PTLD with focal areas of transformation to a monomorphic PTLD resembling large cell immunoblastic lymphoma (Figure 2) 
Discussion
Three decades ago, lymphoproliferative disorders were first recognized to occur after organ transplantation. 1 The incidence of PTLD is greater after solid organ transplantation but PTLD has been frequently seen after T cell-depleted allogeneic bone marrow transplantation. 5, [7] [8] [9] [10] [11] 16 In immunosuppressed individuals, T cell suppression of EBV-induced B cell proliferation is hampered, leading to unrestricted proliferation with a spectrum of morphologic and molecular features that differs from one patient to another and from one site to the other in the same patient. This lymphoproliferation can eventually progress to a monoclonal population. 2, 6, 17 Epstein-Barr virus has been detected in lymphoproliferative disorders occurring in immune deficiency states such as X-linked agammaglobulinemia, isolated immunoglobulin deficiencies, adult common variable immunodeficiency syndrome, X-linked lymphoproliferative syndrome, Wiskott-Aldrich syndrome, ataxia-telangectasia and infection with human immunodeficiency virus, suggesting that EBV has a role in the pathogenesis of these disorders as well. [18] [19] [20] [21] Risk factors for development of PTLD after transplant include EBV seronegativity, type of organ transplanted, type of immunosuppressive agent used, positive serology for CMV and episodes of rejection requiring use of OKT3. 22, 23 In allogeneic BMT patients, other risk factors have been identified including the use of T cell-depleted marrow, donor/recipient mismatch and graft-versus-host disease. 10, 11 We have presented two cases of PTLD occurring after autologous BMT. Epstein-Barr virus titers were not obtained from these patients and therefore it is impossible to determine if the EBV infection was a primary event or a reactivation.
The occurrence of PTLD in these patients may be due to various factors. Delayed immune reconstitution after autologous BMT may play a role although most patients who undergo autologous BMT do not develop PTLD. In both patients, immunosuppression was likely worsened with steroids. Patient 1 had Hodgkin's disease which is associated with long-standing immunological depression even in patients who achieve remission or cure. 24 Infection with PCP and CMV was indicative of ongoing immunosuppression.
To our knowledge, there are only five other reported cases of PTLD after autologous BMT. [12] [13] [14] [15] Chao et al 12 reported a 28-year-old male who developed fever, abdominal pain and dyspnea after autologous BMT for NHL. At necropsy, he was found to have widespread lymphocytic infiltrates with lambda light chain restriction indicating a monoclonal cell population. In situ hybridization demonstrated the presence of EBV genome. Interestingly, this patient's bone marrow had been purged with anti-B cell monoclonal antibodies. Shepherd et al 13 reported a polyclonal PTLD in a 56-year-old patient who developed fevers and mediastinal adenopathy after autologous BMT for CML. Polymerase chain reaction (PCR) for EBV DNA was positive. This patient was successfully treated with methylprednisolone, acyclovir and interferon alpha with no evidence of PTLD at 5 years follow-up.
Briz et al 14 described a 47-year-old man who developed fever following autologous BMT for T cell acute lymphoblastic leukemia. A biopsy of a nasopharyngeal mass showed B cell lymphoma with presence of LMP. He was treated with vincristine, acyclovir, prednisone and radiation therapy without response. The bone marrow had been purged with T cell-specific monoclonal antibodies. 14 Young et al 15 reported a 27-year-old male who developed fever, pharyngitis with cervical and axillary lymphadenopathy after an autologous BMT for T cell lymphoblastic lymphoma. The bone marrow had been purged with T cell-specific monoclonal antibodies. Biopsy showed a monoclonal B cell lymphoproliferation. He died from hepatic and renal failure following treatment with acyclovir, methotrexate and leucovorin. At autopsy, there was no evidence of PTLD. A second patient was reported in the same article. This patient developed PTLD after autologous BMT for T cell lymphoblastic lymphoma, although little clinical data were provided.
Both patients in our report received acyclovir and developed PTLD despite the use of this antiviral agent. Patient 1 received acyclovir prior to diagnosis and was receiving intravenous ganciclovir at the time PTLD was diagnosed. Patient 2 received acyclovir from the time of transplant due to positive herpes simplex serology. The patients in three other reports were also treated with acyclovir and steroids. [13] [14] [15] The favorable outcome in the patient described by Shepherd et al may be due to the polyclonal nature of the lymphoproliferation although Patient 1 in our series also had a polyclonal PTLD. Acyclovir is frequently used in an attempt to control PTLD, but it has minimal activity in the replicative phase of EBV infection. 25 In the reports by Briz and Young, the patients received bone marrow purged with T cell-specific monoclonal antibody. This T cell depletion could increase the risk for developing PTLD, much as it does in allogeneic BMT. 10, 11 Specific recommendations regarding therapy are difficult to make given the small number of reported cases. Decreasing immunosuppression is not an option in these patients. The role of antivirals is controversial and did not appear to benefit our patients. Five of the seven reported patients received acyclovir and/or ganciclovir, but only one patient survived. Chemotherapy was given to three patients with only one of these surviving. Furthermore, chemotherapy may be difficult to tolerate in the post-transplant setting.
Use of T cell infusions and monoclonal anti-B cell antibodies has been used with limited success in PTLD after allogeneic BMT but, to our knowledge, these treatments have not been attempted in patients with PTLD after autologous BMT. 26, 27 Immune modulation with interferon (used by Shephard et al) is another option but little can be said about its effectiveness based on one case.
To conclude, post-transplant lymphoproliferative disorders can develop after autologous bone marrow transplantation. The symptoms of PTLD are frequently nonspecific; thus, this condition may be under-diagnosed. Post-transplant lymphoproliferative disorders should be considered in the differential diagnosis of any BMT patient with adenopathy, unexplained fever or pulmonary infiltrates. The use of bone marrow purged with T cell-specific monoclonal antibody may increase the risk for the development of PTLD in these patients.
